CB1 Receptors on Brain Support Cells May Worsen Multiple Sclerosis

Mice with astrocyte-specific CB1 receptor deletion showed reduced demyelination, attenuated astrocyte reactivity, and improved clinical deficits in EAE (MS model). The protection came from restricted immune cell infiltration and preserved blood-brain barrier function, not from changes in myelin repair.

Preclinical study using complementary mouse models of MS (EAE and lysolecithin-induced lesions). Employed conditional genetic deletion of CB1 receptors specifically in astrocytes, with assessments of clinical scores, demyelination, immune infiltration, BBB function, and oligodendrocyte populations.

This challenges the simple view that cannabinoids are always protective in MS. While cannabinoids help through neurons and oligodendrocytes, this study reveals that CB1 receptors on astrocytes actually promote inflammation and blood-brain barrier breakdown — a paradoxical, cell-type-specific effect.

The endocannabinoid system's effects in MS depend heavily on which cell type is involved. Neurons and oligodendrocytes benefit from CB1 activation, but astrocytes apparently use CB1 signaling to promote inflammation. Future MS therapies may need to be cell-type selective.

Mouse models of MS don't perfectly replicate human disease. Genetic deletion is lifelong, unlike therapeutic intervention. Cannot directly predict how cannabis use affects human MS. EAE is an acute model that may not reflect progressive MS.